<code id='D352B41FF3'></code><style id='D352B41FF3'></style>
    • <acronym id='D352B41FF3'></acronym>
      <center id='D352B41FF3'><center id='D352B41FF3'><tfoot id='D352B41FF3'></tfoot></center><abbr id='D352B41FF3'><dir id='D352B41FF3'><tfoot id='D352B41FF3'></tfoot><noframes id='D352B41FF3'>

    • <optgroup id='D352B41FF3'><strike id='D352B41FF3'><sup id='D352B41FF3'></sup></strike><code id='D352B41FF3'></code></optgroup>
        1. <b id='D352B41FF3'><label id='D352B41FF3'><select id='D352B41FF3'><dt id='D352B41FF3'><span id='D352B41FF3'></span></dt></select></label></b><u id='D352B41FF3'></u>
          <i id='D352B41FF3'><strike id='D352B41FF3'><tt id='D352B41FF3'><pre id='D352B41FF3'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:54

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In